|
Marc A. McKithen is an associate in the Intellectual Property Practice Group and the General Litigation Group in the New York Office of Milbank, Tweed, Hadley & McCloy LLP. He specializes in patent litigation for the pharmaceutical and chemical arts. Notably, he has been involved with the In re Omepazole Litigation (S.D.N.Y. pending) and the Bristol-Myers Squibb v. Rhone-Poulenc, Inc. litigation (Fed. Cir. 2003).
Mr. McKithen's litigation practice has focused on a wide range of pharmaceutical products, such as anti-cancer, anti-thrombinotics, anti-diabetes, cholesterol-lowering agents, and gastrointestinal products. He also has considerable expertise in counseling related to compliance with the Hatch-Waxman Act.
Mr. McKithen earned his B.S. in Chemistry from Rider University, M.S. in Chemistry from the University of North Carolina at Chapel Hill, and J.D. from the Benjamin N. Cardozo School of Law. He is a member and actively involved with committees at the Association of the Bar of the City of New York and the American Chemical Society. He is also admitted to the bar in New York and New Jersey. | 